X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Merck Ltd with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

MERCK vs VENUS REMEDIES - Comparison Results

MERCK    Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    MERCK VENUS REMEDIES MERCK/
VENUS REMEDIES
 
P/E (TTM) x 51.5 -1.0 - View Chart
P/BV x 9.0 0.1 11,596.1% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 MERCK   VENUS REMEDIES
EQUITY SHARE DATA
    MERCK
Dec-17
VENUS REMEDIES
Mar-18
MERCK/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,358126 1,078.2%   
Low Rs93361 1,527.0%   
Sales per share (Unadj.) Rs665.0301.8 220.4%  
Earnings per share (Unadj.) Rs56.6-24.9 -227.5%  
Cash flow per share (Unadj.) Rs72.52.5 2,848.3%  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %1.30-  
Book value per share (Unadj.) Rs441.7293.3 150.6%  
Shares outstanding (eoy) m16.6012.34 134.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.70.3 555.8%   
Avg P/E ratio x20.2-3.8 -538.5%  
P/CF ratio (eoy) x15.836.7 43.0%  
Price / Book Value ratio x2.60.3 813.3%  
Dividend payout %26.50-   
Avg Mkt Cap Rs m19,0111,154 1,647.7%   
No. of employees `0001.50.9 166.9%   
Total wages/salary Rs m1,696393 431.5%   
Avg. sales/employee Rs Th7,150.04,026.1 177.6%   
Avg. wages/employee Rs Th1,098.7425.0 258.5%   
Avg. net profit/employee Rs Th608.2-331.8 -183.3%   
INCOME DATA
Net Sales Rs m11,0403,724 296.4%  
Other income Rs m24023 1,065.3%   
Total revenues Rs m11,2793,747 301.1%   
Gross profit Rs m1,376395 348.6%  
Depreciation Rs m264338 78.0%   
Interest Rs m0354 0.0%   
Profit before tax Rs m1,352-275 -491.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1700-   
Tax Rs m58332 1,844.3%   
Profit after tax Rs m939-307 -306.0%  
Gross profit margin %12.510.6 117.6%  
Effective tax rate %43.1-11.5 -375.6%   
Net profit margin %8.5-8.2 -103.2%  
BALANCE SHEET DATA
Current assets Rs m7,5232,638 285.2%   
Current liabilities Rs m2,2532,305 97.7%   
Net working cap to sales %47.78.9 533.9%  
Current ratio x3.31.1 291.8%  
Inventory Days Days52135 38.5%  
Debtors Days Days4146 87.5%  
Net fixed assets Rs m1,2404,871 25.5%   
Share capital Rs m166123 134.5%   
"Free" reserves Rs m7,1673,496 205.0%   
Net worth Rs m7,3333,619 202.6%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m9,9127,509 132.0%  
Interest coverage xNM0.2-  
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.10.5 224.6%   
Return on assets %9.50.6 1,500.8%  
Return on equity %12.8-8.5 -151.0%  
Return on capital %20.81.6 1,311.9%  
Exports to sales %00-   
Imports to sales %013.9 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA517 0.0%   
Fx inflow Rs m1,0150-   
Fx outflow Rs m3,043517 589.1%   
Net fx Rs m-2,028-517 392.6%   
CASH FLOW
From Operations Rs m537514 104.3%  
From Investments Rs m-476-123 386.9%  
From Financial Activity Rs m-220-387 56.8%  
Net Cashflow Rs m-1604 -3,797.6%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 51.8 0.0 -  
Indian inst/Mut Fund % 18.2 0.2 10,111.1%  
FIIs % 1.0 0.6 172.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 66.4 43.8%  
Shareholders   28,591 20,121 142.1%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare MERCK With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare MERCK With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Over 300 Points Higher; Energy and Metal Stocks Witness Buying(Closing)

After opening the day marginally lower, Indian share markets witnessed most of the buying interest during closing hours and ended their trading session on a strong note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

More Views on News

Most Popular

7 Stocks That Will Remain Evergreen in this Era of Technological Disruption(The 5 Minute Wrapup)

Jun 13, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

Kenneth Andrade Would Like Our Real Estate Stock Recommendation with Triple Digit Upside(The 5 Minute Wrapup)

Jun 12, 2019

This real estate stock recommended in Smart Money Secrets offers the most favourable upside potential.

Why I Believe Smallcaps Will Catch up to the Sensex(Profit Hunter)

Jun 14, 2019

Smallcaps have gone nowhere even as the Sensex makes new all-time highs. Find out why Richa believes this a good opportunity to invest in smallcaps.

Why Super Investor Kenneth Andrade is Bullish on Agri Stocks...and So Are We(The 5 Minute Wrapup)

Jun 21, 2019

Andrade gives his take on agriculture, an industry from which we have already recommended two stocks.

7 Bluechips to Profit from Tech Disruption(Profit Hunter)

Jun 17, 2019

We are living in an era of disruption. Are your stocks well equipped to adapt to changes that disruption will bring along?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

MERCK SHARE PRICE


Jun 25, 2019 03:37 PM

TRACK MERCK

COMPARE MERCK WITH

MARKET STATS